Platelet-activating factor (PAF)-like oxidized phospholipids: Relevance to atherosclerosis

被引:25
|
作者
Tokumura, A [1 ]
Sumida, T [1 ]
Toujima, M [1 ]
Kogure, K [1 ]
Fukuzawa, K [1 ]
机构
[1] Univ Tokushima, Fac Pharmaceut Sci, Tokushima 7708505, Japan
关键词
platelet-activating factor; oxidized phosphatidylcholine; oxidized low density lipoprotein; atherosclerosis;
D O I
10.1002/biof.5520130106
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Lipid peroxidation is involved in the pathogenesis of chronic diseases including atherosclerosis. Oxidized lipoprotein has diverse biological activities and is believed to initiate atheroma formation and maturate fatty plaque. The active components of oxidized lipoproteins still remain to be clarified, but a likely candidate is the phosphatidylcholine (PC) having an sn-2-short-chain acyl group with a methyl, hydroxyl, aldehydic or carboxylic terminal. These unique PCs, formed by oxidative fragmentation of the polyunsaturated acyl group of the parent PC in liposomes, low density lipoproteins and blood plasma, induce platelet aggregation through the activation of the receptor for platelet-activating factor (PAF), due to their resemblance in structure with PAF. We have found that PAF-like lipids regulate DNA synthesis acid production of nitric oxide independently of the activation of the PAF receptor in vascular smooth muscle cells. Regulation of vascular cell function through two distinct signaling pathways mediated by PAF-like lipids provides new insight into the mechanism of induction of atherosclerosis.
引用
收藏
页码:29 / 33
页数:5
相关论文
共 50 条
  • [31] RELEASE OF PLATELET-ACTIVATING FACTOR (PAF) BY MACROPHAGES DURING PHAGOCYTOSIS
    BENVENISTE, J
    MENCIAHUERTA, JM
    FEDERATION PROCEEDINGS, 1978, 37 (06) : 1554 - 1554
  • [32] Inflammatory actions of platelet-activating factor: Control by PAF acetylhydrolase
    Prescott, SM
    JOURNAL OF INVESTIGATIONAL ALLERGOLOGY & CLINICAL IMMUNOLOGY, 1997, 7 (05): : 416 - 416
  • [33] Prevention of cyclosporin nephrotoxicity with a platelet-activating factor (PAF) antagonist
    Bagnis, C
    Deray, G
    Dubois, M
    Pirotzky, E
    Jacquiaud, C
    Baghos, W
    Aupetit, B
    Braquet, P
    Jacobs, C
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 1996, 11 (03) : 507 - 513
  • [34] Mechanisms of platelet-activating factor (PAF)-mediated responses in the lung
    Uhlig, S
    Göggel, R
    Engel, S
    PHARMACOLOGICAL REPORTS, 2005, 57 : 206 - 221
  • [35] PLATELET-ACTIVATING FACTOR (PAF) AS A MEDIATOR OF NEUTROPHIL-PLATELET INTERACTIONS IN INFLAMMATION
    HENSON, PM
    AGENTS AND ACTIONS, 1981, 11 (6-7): : 545 - 547
  • [36] Platelet-activating factor (PAF) receptor and genetically engineered PAF receptor mutant mice
    Ishii, S
    Shimizu, T
    PROGRESS IN LIPID RESEARCH, 2000, 39 (01) : 41 - 82
  • [37] Structural identification of non-platelet-activating-factor-like oxidized phospholipids that induce platelet activation
    Sellmayer, A
    Göpfert, M
    Koerner, S
    Siedler, F
    Siess, W
    EUROPEAN HEART JOURNAL, 2001, 22 : 275 - 275
  • [38] Expression of platelet-activating factor receptor in human carotid atherosclerotic plaques -: Relevance to progression of atherosclerosis
    Brochériou, I
    Stengel, D
    Mattsson-Hultén, L
    Stankova, J
    Rola-Pleszczynski, M
    Koskas, F
    Wiklund, O
    Le Charpentier, Y
    Ninio, E
    CIRCULATION, 2000, 102 (21) : 2569 - 2575
  • [39] Platelet-activating factor and cardiac diseases: Therapeutic potential for PAF inhibitors
    Feuerstein, G
    Rabinovici, R
    Leor, J
    Winkler, JD
    Vonhof, S
    JOURNAL OF LIPID MEDIATORS AND CELL SIGNALLING, 1997, 15 (03): : 255 - 284
  • [40] PRESSURE EFFECTS AND EXTRACTION OF PLATELET-ACTIVATING FACTOR (PAF) IN THE ISOLATED LUNG
    FRIEDRICH, T
    LICHEY, J
    FRANKE, J
    OEFF, K
    NIGAM, S
    PRIESNITZ, M
    SINHAR, P
    BULLETIN EUROPEEN DE PHYSIOPATHOLOGIE RESPIRATOIRE-CLINICAL RESPIRATORY PHYSIOLOGY, 1982, 18 (06): : P140 - P140